Cargando…
PARP inhibitor ABT-888 affects response of MDA-MB-231 cells to doxorubicin treatment, targeting Snail expression
To overcome cancer cells resistance to pharmacological therapy, the development of new therapeutic approaches becomes urgent. For this purpose, the use of poly(ADP-ribose) polymerase (PARP) inhibitors in combination with other cytotoxic agents could represent an efficacious strategy. Poly(ADP-ribosy...
Autores principales: | Mariano, Germano, Ricciardi, Maria Rosaria, Trisciuoglio, Daniela, Zampieri, Michele, Ciccarone, Fabio, Guastafierro, Tiziana, Calabrese, Roberta, Valentini, Elisabetta, Tafuri, Agostino, Del Bufalo, Donatella, Caiafa, Paola, Reale, Anna |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4558132/ https://www.ncbi.nlm.nih.gov/pubmed/25938539 |
Ejemplares similares
-
PARP inhibition and the radiosensitizing effects of the PARP inhibitor ABT-888 in in vitro hepatocellular carcinoma models
por: Guillot, Clément, et al.
Publicado: (2014) -
The PARP inhibitor ABT-888 potentiates darbazine-induced cell death in carcinoids
por: Somnay, Yash, et al.
Publicado: (2016) -
ADP-ribose polymers localized on Ctcf–Parp1–Dnmt1 complex prevent methylation of Ctcf target sites
por: Zampieri, Michele, et al.
Publicado: (2011) -
Poly(ADP-ribosyl)ation is involved in the epigenetic control of TET1 gene transcription
por: Ciccarone, Fabio, et al.
Publicado: (2014) -
Evaluation of Concurrent Radiation, Temozolomide and ABT-888 Treatment Followed by Maintenance Therapy with Temozolomide and ABT-888 in a Genetically Engineered Glioblastoma Mouse Model
por: Lemasson, Benjamin, et al.
Publicado: (2016)